CA-XPRIZE
XPRIZE , the global leader in incentivized prize competitions, in partnership with ANA , Japan’s 5-star airline, announce Avatars Inc , a unique online anthology that blends original science fiction stories with a writing competition to imagine novel use-cases of telepresence technology in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005209/en/
The anthology, edited by Ann VanderMeer, includes 24 original pieces by high-profile authors including James SA Corey, Adrian Tchaikovsky, Tade Thompson, Pat Cadigan, JY Yang, Ken Liu, Charles Yu, Paul McAuley, K Chess, Johanna Sinisalo, and Aliette de Bodard.
The premise for the anthology is as follows:
Established in 2038, Avatars Inc is the world’s leading producer of robotic avatar systems that can transport a human’s senses, actions, and presence to a remote location in real time. For the next few decades, they developed hundreds of avatar models and enabled millions of operator-hours. In 2080, a campaign was underway to physically retrieve, preserve and archive the memories from their most valuable units. We have been searching the world, and even deep into the solar system, to acquire the chips that contain avatar memories spanning the 21st century. These are those memories.
The short story contest is open through May 8, 2020 and is open to anyone over the age of 18 who submits an original story between 2,500 – 3,500 words, bringing to life a ‘missing’ avatar memory. Members of XPRIZE’s Science Fiction Advisory Council will vote on the finalist pieces to select the grand prize winner, who will then receive a prize package including a 3.2GHz 8-core Intel Xeon W Processor iMac Pro, a GoPro Hero7 Camera, Sony noise cancelling headphones, a 32GB Kindle Paperwhite, a JoneR Universal Translator, and more.
The fictional Avatars Inc was inspired by the real-life $10 million ANA Avatar XPRIZE , a four-year global competition focused on the development of an avatar system that can transport a human’s senses, actions, and presence to a remote location in real time. The competition was launched in March 2018 at South by Southwest (SXSW) in Austin.
“The world of Avatars Inc was made possible by the incredible partnership between XPRIZE and ANA and is intended to elevate the overall conversation about avatars among the general public, making the topic of avatars accessible, relevant and exciting, while creating demand and interest in the technologies that will result from the ANA Avatar XPRIZE,” said David Locke, Prize Lead of the ANA Avatar XPRIZE.
As of January 2020, a total of 77 teams from 19 countries qualified to compete. In March 2022, up to 20 teams will compete in the finals, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use-case scenarios. The first-place winner will receive $5 million.
To explore the world of Avatars Inc, and to submit your short story, visit http://www.avatars.inc .
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005209/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom